Charts Ocugen, Inc. Börse Stuttgart

Stocks

2H51

US67577C1053

Biotechnology & Medical Research

Market Closed - Börse Stuttgart 20:46:06 08/09/2026 BST			5-day change	1st Jan Change
1.142 ^EUR	-3.22%		+5.55%	-7.45%

09-01	Ocugen Doses First Patient in Trial of Potential Eye Disease Drug	MT
09-01	Ocugen Doses First Patient in Phase 3 Registrational Trial of Ocu410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration	CI

Chart: Technical Analysis

Börse StuttgartEUR

Markets		Quality
Nasdaq	OCGN	Delayed
CBOE	OCGN	Real-time
Tradegate	2H51	Real-time
Boerse Muenchen	2H51	Real-time
Börse Stuttgart	2H51	Delayed
Mexican S.E.	OCGN *	End-of-day quote
Deutsche Boerse AG	2H51	Delayed

ProRealTime Chart

MarketScreener's Technical Analysis Ratings

Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!

SEIZE THE OFFER!